GlobeImmune, Inc. GBIM

Company Overview

GlobeImmune, Inc. (NASDAQ: GBIM) was a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapies for infectious diseases and cancer. The company operated within the biotechnology and immuno-oncology sectors and was primarily known for its proprietary Tarmogen® platform, a yeast-based therapeutic technology designed to stimulate targeted T-cell immune responses. Its development programs concentrated on hepatitis B, cancer immunotherapy, and other chronic disease applications.

The company’s principal revenue sources historically came from research collaborations, licensing agreements, and milestone payments rather than commercial product sales, as GlobeImmune did not commercialize approved therapies during its operating history. GlobeImmune was founded in 1995 and evolved from an early-stage biotechnology research company into a clinical development organization with strategic partnerships involving larger pharmaceutical firms. Public filings and historical corporate disclosures indicate that the company’s operations became increasingly limited following clinical setbacks and restructuring activities. Data regarding the company’s current operating status is inconclusive based on available public sources.